Volume 2, Issue 4
Editorialp. 339-342
Opportunities for innovation in the design and execution of clinical trials
Author(s): John J Orloff, Jeffrey Kralstein
Editorialp. 343-346
Patient-reported outcomes in clinical practice: using standards to break down barriers
Author(s): Michael D Brundage & Claire F Snyder
Interviewp. 351-354
Ethical issues of placebo-controlled clinical trials in multiple sclerosis
Author(s): Jeffrey A Cohen
News and Viewsp. 355–358
Specific antipsychotic drugs prescribed for dementia could increase mortality
Review: Clinical Trail Outcomesp. 359-370
Approaches to clinical trials of new anti-tuberculous drugs
Author(s): Charles M Bark, Jennifer J Furin & John L Johnson
Therapeutic Perspectivep. 371-385
Therapeutic potential of hedgehog signaling inhibitors in cancer: rationale and clinical data
Author(s): Blake T Aftab, Charles M Rudin
Therapeutic Perspectivep. 387-396
Src tyrosine kinase inhibitors in the treatment of lung cancer: rationale and clinical data
Author(s): Sacha I Rothschild,Oliver Gautschi
Review: Clinical Trail Outcomesp. 397-402
New developments in the treatment of chronic thromboembolic pulmonary hypertension*** Pharmacological treatment of CTEPH
Author(s): Irene M Lang
Review: Clinical Trail Outcomesp. 403-416
Peripheral T-cell lymphoma: pharmacotherapy overview
Author(s): Maher Abdul-Hay, Jasmine Zain
Review: Clinical Trail Outcomesp. 417-421
IL-17 in systemic lupus erythematosus
Author(s): Wu Qian, Antonio La Cava
Review: Clinical Trail Outcomesp. 423-432
Safety and efficacy of transdermal testosterone for treatment of hypoactive sexual desire disorder
Author(s): Talya Waldman, Chrisandra L Shufelt, Glenn D Braunstein
Review: Clinical Trail Outcomesp. 433-440
Ranibizumab for the treatment of visual impairment due to diabetic macular edema: evidence from recent clinical trials
Author(s): Laura Distefano, Anna Espax Boixadera, Charlotte Wolley-Dod, Vicente Martnez-Castillo, Jose Garcia-Arumi
